Edgewise Therapeutics (EWTX) Gains from Investment Securities (2020 - 2026)

Edgewise Therapeutics has disclosed Gains from Investment Securities across 7 years of filings, most recently posting $688500.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $688500.0, down 86.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $688500.0 (down 86.34% YoY), and the FY2025 annual result was $1.0 million, down 93.45% from the prior year.
• Gains from Investment Securities came in at $688500.0 for Q1 2026 at Edgewise Therapeutics, down from $1.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $15.4 million in Q4 2024 to a low of $335248.0 in Q2 2022.
• The 5-year median for Gains from Investment Securities is $2.0 million (2025), against an average of $3.3 million.
• Peak annual rise in Gains from Investment Securities reached 804.8% in 2025, while the deepest fall reached 93.45% in 2025.
• Edgewise Therapeutics' Gains from Investment Securities stood at $2.9 million in 2022, then soared by 70.98% to $5.0 million in 2023, then jumped by 205.89% to $15.4 million in 2024, then slumped by 93.45% to $1.0 million in 2025, then plunged by 31.81% to $688500.0 in 2026.
• The last three Gains from Investment Securities figures came in at $688500.0 (Q1 2026), $1.0 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.